Corpus Intelligence IC Memo — CHESTNUT HILL HOSPITAL 2026-04-26 12:05 UTC
IC Memo — CHESTNUT HILL HOSPITAL
Investment Committee Memorandum | PA | 128 beds | Grade C | EBITDA uplift $10.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CHESTNUT HILL HOSPITAL

CCN 390026 | PHILADELPHIA, PA | 128 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CHESTNUT HILL HOSPITAL is a 128-bed suburban community hospital in PHILADELPHIA, PA with $137.2M in net patient revenue and a -13.2% operating margin. The hospital serves a payer mix of 37.3% Medicare, 0.7% Medicaid, and 62.1% commercial.

Thesis: Undervalued. Our ML models identify $10.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -13.2% to -5.8% (+736bps).

Net Revenue HCRIS$137.2M
Current EBITDA COMPUTED$-18.1M
Operating Margin COMPUTED-13.2%
Occupancy HCRIS60.1%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS11.4%
Distress Probability ML43.6%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
105
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -13.2% places it below the state median. Among 105 size-comparable peers (64-256 beds), the median margin is -6.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (64-256), prioritizing same-state peers. 105 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CHESTNUT HILL HOSPITAL (Target)PA128$137.2M-13.2%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
ROBERT PACKER HOSPITALPA252$471.8M-2.1%
WILLIAMSPORT HOSPITAL & MEDICAPA227$459.8M-8.4%
MOUNT NITTANY MEDICAL CENTERPA248$441.7M12.6%
MEMORIAL MEDICAL CENTERPA241$435.1M-21.2%
THE CHAMBERSBURG HOSPITALPA234$435.1M5.2%
ST LUKE HOSPITAL ANDERSON CAMPPA193$433.0M20.6%
DUBOIS REGIONAL MEDICAL CENTERPA247$429.3M-15.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.9M+210bp18mo
Cost to Collect4.5%2.5%$2.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$88K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.9M
Cost to Collect
$2.7M
Denial Rate Reduction
$2.7M
A/R Days Reduction
$1.7M
Clean Claim Rate
$88K
Total EBITDA Uplift$10.1M
Current EBITDA$-18.1M
+ RCM Uplift+$10.1M
Pro Forma EBITDA$-8.0M
Current Margin-13.2%
Pro Forma Margin-5.8%
WC Released (1x)$5.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-27.8M$-18.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-27.8M$-29.1M0.00x-100.0%
Bull Case9.0x11.0x$-25.0M$-4.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-25.0M$-12.7M0.00x-100.0%
Bear Case11.0x10.0x$-30.6M$-59.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-30.6M$-75.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 105 hospitals with 64-256 beds
  • Same-state prioritization (n=106)
  • Comp margins: P25=-18.6% / P50=-6.5% / P75=5.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.